1014 Angiotensin II for Vasoplegic Shock After Cardiac Surgery: Systematic Review and Meta-Analysis
British Journal of Surgery · 10.07.2026 · 113 (Supplement_6)
DOI: 10.1093/bjs/znag063.313 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Surgery, online erschienen am 10.07.2026. Verfasst von H Zaidi und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Aim
Vasoplegic shock after cardiopulmonary bypass (CPB) is a cause of postoperative morbidity and mortality. Angiotensin II (Ang II) has been introduced as a rescue vasopressor, but its evidence base for use post-cardiac surgery remains limited.
Method
We conducted the first systematic review and meta-analysis on this subject, following a search of Embase and Medline (2017–2025) that returned 124 studies for title and screening. 94 papers proceeded to full text screening for peer-reviewed studies concerning adults receiving Ang II for vasoplegic shock after CPB. Eligible designs included randomised, cohort, and case-series studies with four-or-more patients. The primary endpoint was all-cause mortality (in-hospital or 30-day). Mortality proportions were pooled using a random-effects model. Secondary outcomes included haemodynamic response, vasopressor requirements, and adverse events.
Results
Six studies (total 139 Ang II-treated patients) met our inclusion criteria. Four studies (n = 113; 46 deaths) yielded a pooled mortality of 40.5 % (95 % CI 31.6-50.1; I² = 6 %). Across datasets reporting haemodynamics at 3 hours, pooled ΔMAP was +5.4 mm Hg across studies (combining early/late administration within studies); restricting to early administered Ang II cohorts, pooled ΔMAP was +7.5 mm Hg. Pooled change in noradrenaline equivalent dosage (ΔNED) was -0.13 µg/kg/min, indicating reduced catecholamine exposure. Adverse events included thrombosis and new renal replacement therapy.
Conclusions
Angiotensin II produces rapid improvement in blood pressure and catecholamine sparing in postcardiac vasoplegia. Despite encouraging physiologic effects, pooled in-hospital mortality remains a concern. Larger multicenter trials with standardised endpoints are required to determine survival benefit.
Zitieren
APA
Zaidi, H., Zaidi, H., & Singh, R. (2026). 1014 Angiotensin II for Vasoplegic Shock After Cardiac Surgery: Systematic Review and Meta-Analysis. British Journal of Surgery, 113(Supplement_6). https://doi.org/10.1093/bjs/znag063.313
Vancouver
Zaidi H, Zaidi H, Singh R. 1014 Angiotensin II for Vasoplegic Shock After Cardiac Surgery: Systematic Review and Meta-Analysis. British Journal of Surgery. 2026;113(Supplement_6). doi:10.1093/bjs/znag063.313
BibTeX
@article{Zaidi2026,
author = {Zaidi, H and Zaidi, H and Singh, R},
title = {1014 Angiotensin II for Vasoplegic Shock After Cardiac Surgery: Systematic Review and Meta-Analysis},
journal = {British Journal of Surgery},
year = {2026},
volume = {113},
number = {Supplement_6},
doi = {10.1093/bjs/znag063.313}
}
EUVIMED